Pharmesis to acquire remaining 19% stake in Sichuan Longlife Pharmaceutical

This agreement was finalised on 23 September.

Pharmesis International Ltd. has announced that its wholly-owned subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd., has signed a conditional sale and purchase agreement to acquire the remaining 19% equity interest in Sichuan Longlife Pharmaceutical Co., Ltd.

This agreement was finalised on 23 September.

The equity interest will be acquired from Chengdu Kinna Investment Co., Ltd., under the terms and conditions outlined in the SPA.

The acquisition is part of Pharmesis International's strategic efforts to enhance its portfolio and strengthen its position in the pharmaceutical industry.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia